Sfmg LLC Purchases 66 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sfmg LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,718 shares of the medical research company’s stock after purchasing an additional 66 shares during the quarter. Sfmg LLC’s holdings in Thermo Fisher Scientific were worth $3,035,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Coppell Advisory Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Live Oak Investment Partners acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $37,000. Raleigh Capital Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares in the last quarter. Finally, Cedar Mountain Advisors LLC raised its holdings in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Marc N. Casper sold 5,547 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares in the company, valued at $24,011,436.96. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Evercore ISI upped their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $601.56.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $3.32 during trading on Wednesday, hitting $554.55. 1,010,299 shares of the company were exchanged, compared to its average volume of 1,115,688. The company has a market capitalization of $211.68 billion, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $571.67 and its 200-day moving average is $526.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period last year, the firm posted $5.40 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.